Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bayer, Novartis clash with UK doctors over use of cheap eye drug

Bayer is weighing legal action and Novartis has expressed concern at plans by doctors in the north of England to defy official guidance by using a cancer medicine as a cheap eye drug.

Read More »

Daiichi Sankyo’s Tumor Drug Meets Primary Endpoint in Late-Stage Study

Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.

Read More »

X-Spine Systems to Shut Down, Lays Off 54 Employees

X-Spine Systems, a division of Xtant Medical Systems, is shutting down a facility in Ohio and terminating 54 people between December and February 2018.

Read More »

Kirin Cashes Out of Amgen Drug Joint Venture for $780 Million

Amgen and Kirin Holdings decided to dissolve their joint venture, Kirin-Amgen, which will become a wholly owned subsidiary of Amgen.

Read More »

New Jersey sues OxyContin maker, links marketing to opioid crisis

New Jersey sued Purdue Pharma LP, maker of the chronic pain medication OxyContin, accusing the company of engaging in deceptive marketing practices that contributed to what it called the state’s opioid crisis.

Read More »

Voyager Sinks as Sanofi Genzyme Opts Out of Parkinson’s Gene Therapy Program

Shares of Voyager Therapeutics fell more than 12 percent in premarket trading after the company announced Sanofi Genzyme walked away from its $845 million gene therapy treatment for Parkinson’s disease.

Read More »

AstraZeneca, Incyte plan pivotal lung cancer trial

AstraZeneca stepped up its bet on immunotherapy combo treatments to fight lung cancer by signing a deal with Incyte as they will start a final-stage study in 2018.

Read More »

U.S. states allege broad generic drug price-fixing collusion

A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving to widen an earlier lawsuit to add many more drugmakers and medicines in an action that sent some company shares tumbling.

Read More »

Pfizer beats Q3 2017 profit estimates

Pfizer Inc.’s third-quarter profit beat market estimates and the company raised its full-year 2017 earnings forecast.

Read More »

Merck Drops After Withdrawing European App for Wonder Drug Keytruda

Merck announced that the company pulled its application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer from the European Medicines Agency.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom